Diabetes complications

Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction

Cardiovasc DiabetolPublished Cohort study

Main finding · Composite eventsResult — go to the resultAdjusted hazard ratio 2.34 95% CI 1.49–3.67

Authors' conclusion

Elevated SHR was independently associated with an increased risk for composite events of all-cause, cardiovascular mortality, and HF readmission than those with lower SHR. SHR is a valuable tool for predicting and stratifying long-term adverse risks among HFpEF patients.

Study context

Population
HF with preserved ejection fraction (HFpEF) patients enrolled between 2015 and 2023
Participants
400 patients
Exposure
High stress hyperglycemia ratio (SHR) vs low SHR
  • High SHRn = 124
  • Low SHRn = 276reference
Outcome
Composite of:
  • All-cause mortality
  • Cardiovascular mortality
  • Heart failure (HF) rehospitalization
Follow-up
Mean 41 months
Methodological detailsOptimal SHR cut-off 0.99 identified by ROC analysis
  • Optimal SHR cut-off 0.99 identified by ROC analysis

Main finding

Composite events · 41-month follow-up

Adjusted hazard ratio

2.34

95% CI 1.49–3.67

P < 0.001

High SHRvs Low SHR
aHR 2.34 (95% CI 1.49–3.67); P < 0.001

As reported in the abstract

Patients with composite events
190 (47.5%)

Observational data: associations, not effects.

Further findings

SHR in patients with vs without events

SHR significantly elevated in patients with events
P < 0.001

Prognosis by left ventricular EF (LVEF) and SHR

Poorer prognosis with 50 < LVEF < 60 and SHR > 0.99 vs other groups
log-rank p < 0.001

Incremental prognostic value

Adding SHR to MAGGIC score model gave incremental improvement in predicting adverse events

Correlation with N-terminal pro-brain natriuretic peptide (NT-proBNP)

SHR displayed a slight correlation with NT-proBNP

Original publication

Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction. Cardiovasc Diabetol. Published 13 February 2024. doi:10.1186/s12933-024-02157-7

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.